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Background and purpose: We try to search for speciﬁc serum or urinary biomarkers for the early
detection, follow-up, and prediction of tumor recurrence, progression, and clinical outcome is a difﬁcult
task in individuals with bladder cancer.
Materials and methods: In this study, urinary samples were dialyzed to remove any interfering molecules
and concentration by lyophilization. The urinary proteome maps of 10 healthy volunteers and 10 bladder
transitional cell carcinoma (BTTC) patients were explored through two-dimensional polyacrylamide gel
electrophoresis (2-D PAGE) coupled with mass spectrometry. With no fractionation, the proteome maps
acquired in this study likely represented the total urinary proteins.
Results: Comparative proteomics indicated that six proteins were down-regulated and ﬁve proteins were
up- regulated in BTCC patients as compared with normal. The down-regulated spots were identiﬁed as
human haptoglobin precursor, human heparan sulfate proteoglycan perlecan, inter-alpha-trypsin in-
hibitor heavy chain H4 precursor, and AMBP protein precursor. The up-regulated spots were identiﬁed as
peroxiredoxin 2, heparan sulfate proteoglycan perlecan, protease serine 1 fragment and AMBP protein
precursor. Most of these de-regulated proteins were extracellular matrixeassociated proteins, which
may play roles in regulating the immune response, signal transduction and tumor invasions.
Conclusion: In this paper, 11 de-regulated proteins were observed in the urinary specimens of BTTC
patients from the southwestern coast of Taiwan where Blackfoot disease is endemic and the unusually
high incidence of BTTC in this area might attribute to high arsenic content in the drinking water. It is
possible that long-term arsenic-induced alteration of these de-regulated proteins, most of which were
extracellularmatrix e (ECM) related proteins which may play roles in regulating the immune response,
signal transduction and tumor invasions, might be involved in BTTC development in southwestern
Taiwan.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).t of Biotechnology, Southern
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The most prevalent cancer of the urinary tract is tumor of the
urinary bladder. It includes a broad range of histological hetero-
geneous tumor types arising mostly from the urothelium lining of
the urinary bladder and ureters, including bladder transitional cell
carcinoma (BTCC), squamous cell carcinoma, adenocarcinoma, and
other less frequent lesions.1 More than 90% of the bladder tumors
are diagnosed as BTCC and the majority of BTCC (70%) are recog-
nized as superﬁcial papillary lesions (stage pTa, T1).1 Recurrencesiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
mor-associated proteins for bladder transitional cell carcinoma in
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progress to higher grade and/or stage or muscle invasion.2
Currently, cytoscopy combined with urine cytology is routinely
used for the diagnosis of BTCCs. Urine cytology is mainly used for
the diagnosis and follow-up of patients with malignancy. It is
noninvasive and offers high speciﬁcity as well as satisfactory
sensitivity for the detection of high-grade BTCCs but lacks sensi-
tivity for low-grade lesions. However, cytoscopy has high speciﬁcity
but is invasive, expensive, and occasionally inconclusive in cases of
high-grade ﬂat tumors and cystitis.3 Because of the aforementioned
blemish, more noninvasive and accurate biomarkers are required
for the diagnosis and prognosis of bladder cancer.
To date, many urinary BTCC biomarkers have been reported.
Among these, bladder tumor antigen (BTA Stat and BTA TRAK),
nuclear matrix protein 22 (NMP-22 enzyme-linked immunosor-
bent assay detection kit), and tumor-associated antigens M344,
19A211, and LDQ19 (ImmunoCyt ﬂuorescence test), ﬁbrinogen-
ﬁbrin degradation products (FDP test), and UroVysion ﬂuorescent
in situ hybridization assay have been approved by the United States
Food and Drug Administration for diagnostic purposes.4 Other
urinary tests such as survivin test, hyaluronidase (HA-Hase test),
BCLA-4, and cytokeratin (Ck)-20 are still being investigated.4,5
Some of these assays have demonstrated higher sensitivity than
the conventional urine cytology, but most display lower speciﬁcity.
In general, these assays are more expensive and may only be per-
formed by experienced personnel. Thus, searching for speciﬁc
serum or urinary biomarkers for the early detection, follow-up, and
prediction of tumor recurrence, progression, and clinical outcome
is a difﬁcult task in individuals with bladder cancer.
In this study, two-dimensional gel electrophoresis (2-DE) was
used to establish the urinary proteome maps of the patients with
BTCC from the southwestern coast where blackfoot disease, which
is caused by the consumption of water contaminated by arsenic, is
endemic. Coupled with tandem mass spectrometry (MS/MS), two-
dimensional gel comparisons between the urinary protein proﬁles
of healthy persons and patients with BTCC were implemented to
ﬁnd the differentially expressed protein present in the patient urine
and these dysregulated proteins might be the potential biomarkers
for diagnosis or prognosis in the future. The results of proteomicTable 1
Clinical information on patients with bladder transitional cell carcinoma and normal
donors.
Case No. Sex/Age (y) Stage Grade
Patients
CM001 F/83 T1 II
CM002 F/77 T2 II
CM003 F/65 T1 II
CM101 M/84 T1 II
CM102 M/72 T1 II
CM103 M/73 T2 III
CM105 M/50 T1 III
CM106 M/77 T2 III
CM107 M/72 T2 III
CM004 F/65 T2 III
Healthy donors
NM001 M/25 d d
NM002 M/25 d d
NM003 M/25 d d
NM004 M/25 d d
NM005 M/25 d d
NM006 M/25 d d
NF001 F/23 d d
NF002 F/23 d d
NF003 F/23 d d
NF004 F/23 d d
F ¼ female; M ¼ male.
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existed in the urine of patients with BTCC from the southwestern
coast of Taiwan and most of these proteins belonged to the extra-
cellular matrix proteins.
2. Materials and methods
2.1. Urine from patients with BTCC
200-mL urine samples collected from each of 10 healthy in-
dividuals or 10 patients with BTCC at Chi-Mei Medical Center
(Tainan, Taiwan), a southwestern medical center proximal to the
blackfoot disease-endemic region in Taiwan, were immediately
transferred to the laboratory, centrifuged at 9300g for 30minutes at
15C using Micromax RF (Thermo IEC) and the supernatant was
frozen at 80C for future proteomic analyses. An informed con-
sent was obtained from each patient and healthy donors. The
clinical information of the patients and control donors are listed in
Table 1. The current study was approved by the Medical Research
Committee of Chi-Mei Medical Center and complies with the
guidelines for human study published by Administration of Health
in Taiwan.
2.2. Preparation of human urinary protein samples
The frozen urine sample was lyophilized within 12 hours of
arrival at the laboratory. Then the powder was dissolved in 30 mL
sterile phosphate buffered saline and the resulting solution was
dialyzed three times in the dialysis membrane (MWCO: 3.5 kDa;
Pierce, Rockford, IL, USA) against 2 L of double distilled water. After
dialysis, the solution was lyophilized again and the protein pellet
was dissolved in 500 mL lysis buffer [7M urea, 2M thiourea, 100mM
dithiothreitol (DTT), 4% (v/v) CHPAS, 40mM Tri-Base (pH 10), 1mM
PMSF, and 1 Complete Mini protease inhibitor cocktail tablet
(Roche, Diagnostics, Indianapolis, IN, USA) per liter] with shaking at
room temperature for 1 hour. Then the lysate was centrifuged at
349,000g (Beckman Coulter, Fullerton, CA, USA) for 2 hours at 15C
in Type 90 Ti rotor and the supernatant was precipitated with a 2-D
clean-up kit (Amersham Bioscience Corp. Piscataway, NJ, USA) ac-
cording to the manufacturer's suggestion. The resulting protein
lysate was measured by Bio-Rad DC protein assay.
2.3. Isoelectric focusing
The pH 4-7, 18-cm immobibline dry strips (GE Healthcare Bio-
Sciences AB, Uppsala, Sweden) were rehydrated for 16 hours at
20C with 300 mL rehydration buffer [7M urea, 2M thiourea, 4% (v/
v) CHAPS, 2% (w/v) DTT, 0.5% (v/v) Immobilized pH gradient (IPG)
buffer and trace of bromophenol blue]. After rehydration, 100 mg of
urinary protein lysates prepared from each of healthy individuals or
bladder cancer patients were cup-loaded onto the rehydrated gel
strips with Ettan IPGphor Cup Loading Manifold (Amersham-
Pharmacia Biotech Inc., Piscataway, NJ, USA). The proteins were
then focused at 20C at 50 V, 100 V, 200 V, 500 V, 1000 V, 5000 V,
and 8000 V, respectively, with a total of 81,434 voltage-hours.
2.4. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
After isoelectric focusing, the gel strips were equilibrated in
equilibration buffer [6M urea, 30% (v/v) glycerol, 2% (w/v) sodium
dodecyl sulfate] containing 2% (w/v) DTT for 15minutes and then in
equilibration buffer containing 5% (w/v) iodoacetamide for an
additional 15 minutes. The equilibrated gel was loaded onto the top
of a 12.5% (w/v) polyacrylamide gel and sealed with 0.5% (w/v)
agarose. The proteins were separated at 420 V using BioRad Proteanmor-associated proteins for bladder transitional cell carcinoma in
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reaching the bottom of the gel.2.5. Silver staining
The silver staining was performed according to the protocol
described in the 2-D Plus One Silver Staining kit (Amersham-
Pharmacia Biotech Inc.). Brieﬂy, the gel was ﬁxed in ﬁxation solu-
tion (ethanol/water/acetic acid, 4/5/1, v/v) after electrophoresis and
treated with sensitizing solutions [0.5M sodium acetate, 0.5% (w/v)
sodium thiosulfate] for 30 minutes. After sensitization, the gels
were washed and incubated in 0.25% (w/v) silver nitrate solution
for 20 minutes and then developed by incubating with the devel-
oping solution [2.5% (w/v) sodium carbonate and 0.015% (v/v)
formaldehyde] until the protein spots appeared. Glutardialdehyde
was not used when staining the gels used for mass spectrometry.2.6. Image analysis
To search for proteins showing disparity in urine, the urinary
proteomes of healthy individuals and patients with BTCC were
analyzed by PDQuest (BioRad, Hercules, CA, USA) software. A total
of 10 pairs of well-focused gels from 10 healthy individuals and 10Figure 1. Urinary proteomes of normal individuals. (A) Female donor. (B) Male donor. (C) Ma
by two-dimensional gel electrophoresis as described in the “Materials and methods” sectio
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compared. Differentially expressed spots identiﬁed by computer
analysis were further conﬁrmed by visualization. The intensity of
the spot was computed and normalized as a percentage of the total
intensity of all spots in a gel and analyzed with Student t test
(Pharm PCS version 4.2; Springer-Verlag, New York, NY, USA). In all
cases, statistical variance of the healthy:BTCC spot intensity ratio
within 95% (Student t test; p < 0.05) was considered to be signiﬁ-
cantly different.2.7. In-gel digestion
The in-gel digestion and mass spectrometric analysis were
performed as described previously, with some modiﬁcations.6 The
spots excised from the gel were incubated in a solution containing
15mM of potassium ferricynate and 50mM sodium thiosulfate until
the brownish color disappeared. The destained gel piece was
washed with 25mM ammonium bicarbonate for 10 minutes and
then with 25mM ammonium bicarbonate/50% acetonitrile for 10
minutes. After drying in SpeedVac (ThermoSavant, Milford, MA,
USA), the gel was incubated with 50 mL of 2% (v/v) 2-
mercaptoethanol in darkness for 20 minutes and an equal volume
of 10% (v/v) vinylpyridine in 25mM ammonium bicarbonate/50%le donor. The urinary proteins were puriﬁed by dialysis and lyophilization and analyzed
n.
mor-associated proteins for bladder transitional cell carcinoma in
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the gel was washed three times with 25mM ammonium bicar-
bonate and dehydrated in 25mM ammonium bicarbonate/50%
acetonitrile. The gel was dried and treated with 50 ng of modiﬁed
trypsin (Amersham-Pharmacia Biotech Inc.) in 100 mL of 25mM
ammonium bicarbonate at 37C overnight. The supernatant was
collected after digestion and the gel was extracted with 200 mL of
0.1% formic acid. The extracts were combined and dried in Speed-
Vac and resuspended in 0.1% formic acid immediately for mass
spectrometric analysis or stored at 20C until use.2.8. Protein identiﬁcation analysis via liquid chromatography-MS/
MS
The protein digest was analyzed in LTQ-Orbitrap hybrid tandem
mass spectrometer (ThermoFisher, San Jose, CA, USA) in-line
coupled with Agilent 1200 nanoﬂow high-performance liquid
chromatography system equippedwith LC Packing C18 PepMap 100,
Thermo Scientiﬁc (Waltham, MA USA) (length: 5 mm; internal
diameter: 300 mm; bead size: 5 mm) as the trap column and Agilent
ZORBAX XDB-C18 (Santa Clara, CA, USA) (length, 50 mm; internal
diameter,: 75 mm; and bead size, 3.5 mm) as the separating column.
File Converter in Xcalibur 2.0SR package (ThermoFisher, San Jose,Figure 2. The consistency of urinary proteomes of normal individuals. (A) Male urine collec
the 1st day. (D) Urine collection from the ﬁfth day. The proteins were isolated from urine a
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information as well as to compute the charge and mass for each
analyzed peptide. TurboSequest program (ThermoFinnegan, San
Jose, CA, USA)was then used to search the best matched peptides
from a human protein database whose FASTA sequences were
downloaded from the National Center for Biotechnology Informa-
tion (http://www.ncbi.nlm.nih.gov/). This protein database was
structured on August 19, 2007 and contained about 410,000 items.
Proteins were identiﬁed onlywhen therewere at least two peptides
matched and both search results had high Xcore (i.e., 2.0 for
doubly charged peptides and3.0 for triply charged ones) andwith
minimal differences between observed and hypothetical masses
(i.e., DM < 10 ppm).3. Results
3.1. The 2-DE analyses of urinary protein samples prepared by
simple lyophilization and dialysis
To investigate if the urinary protein extracts prepared by simple
lyophilization and dialysis procedure as described in the “Materials
and methods” section were appropriate for the 2-DE analyses, the
urine samples collected from one healthy woman and two healthyted on the 1st day. (B) Urine collection from the ﬁfth day. (C) Female urine collected on
s described in Figure 1.
mor-associated proteins for bladder transitional cell carcinoma in
15), http://dx.doi.org/10.1016/j.urols.2015.08.009
C.-C. Su et al. / Urological Science xxx (2015) 1e8 5male volunteers were implemented for the 2-DE examination. The
results of 2-DE analyses demonstrated that the clear 2-DE maps
could be acquired from the female and male healthy donors using
the sample preparation and 2-DE method as described in the
“Materials and methods” section (Figure 1). In addition, a large
disparity could be observed between the female and male protein
proﬁles and even between the different male donors. On average,
500 protein spots were detected in each male and female urinary
proteome, respectively. Furthermore, urinary protein samples iso-
lated from the female and male individuals at different time pointsFigure 3. The representative comparative urinary proteomes of patients with bladder trans
with BTCC. (B1) Proteome of a healthy male patient. (A2) The proteome of a female patient w
were indicated by the arrow plus Arabic numbers, whereas the upregulated spots were sho
molecules and concentration by lyophilization. With no fractionation, the proteome maps
teomics indicated that six proteins were downregulated and ﬁve proteins were upregulate
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analyses. Although the urinary proteome maps at different times
were not identical, each male or female urinary proteome at Day 1
was similar to that at Day 5 (Figure 2). It is very hard to obtain the
identical proteome for each individual at different times because
for every individual the metabolism in each day may not be the
same and in addition the inherent variation might be present in
each silver-stained 2-DE gel. The aforementioned results suggested
that a deﬁned urinary proteome could be obtained by the simple
lyophilization and dialysis.itional cell carcinoma (BTCC) and normal donors. (A1) The proteome of a male patient
ith BTCC. (B2) Proteome of a healthy female patient. The downregulated protein spots
wn by arrow plus numbers. Urinary samples were dialyzed to remove any interfering
acquired in this study likely represented the total urinary proteins. Comparative pro-
d in patients with BTCC compared with normal patients.
mor-associated proteins for bladder transitional cell carcinoma in
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Table 2
Summary of differentially expressed proteins.
Spot Altered expression incidence Patient (ppm) Normal (ppm) p Fold difference
1 5/10 252.6 ± 29.2 1738.6 ± 171.3 <0.05 6.9a
2 6/10 527.2 ± 54.6 3444.4 ± 1937.1 <0.05 13.4
3 7/10 342 ± 24.1 1465.3 ± 97.4 <0.01 4.3
4 4/10 7202 ± 2121.6 15019.9 ± 1568.9 <0.01 2.1
5 4/10 655.8 ± 249.2 15247.9 ± 1743.9 <0.05 23.3
6 2/10 1039.9 ± 93.9 1906.3 ± 129.5 <0.01 1.8
A 4/10 4316.2 ± 2144 923.7 ± 429.3 <0.05 þ2.9b
B 6/10 8361.7 ± 1443.7 1465 ± 344.6 <0.01 þ5.7
C 4/10 18537.7 ± 1024.9 9419.5 ± 113.3 <0.05 þ2
D 4/10 33075.9 ± 2680.2 18074.9 ± 732.6 <0.05 þ1.8
E 2/10 4551.5 ± 165.1 263 ± 72.4 <0.05 þ17
Data are presented as mean ± standard error.
a Downregulation in bladder transitional cell carcinoma (BTCC).
b Upregulation in BTCC.
C.-C. Su et al. / Urological Science xxx (2015) 1e863.2. Differentially protein proﬁles among urinary specimens
belonging to patients with BTCC and healthy volunteers
In order to ﬁnd the potential diagnosis or prognosis biomarkers
for BTCC, 10 independent pairs of 2-DE gel maps were established
by the aforementioned method to compare the urinary proteomes
of neoplastic and non-neoplastic volunteers. The results of 2-DE
gels demonstrated the variability present between the protein
proﬁles of patients with BTCC and controls, among the healthy
individuals, and even between men and women. The representa-
tive 2-DE gels of urinary specimens collected from patients with
BTCC and healthy donors are shown in Figure 3 and ~ 500 proteins
spots were resolved on each gel. Because of the intrinsic variability
attributing to the sample heterogeneity, the neoplastic urinary
proteomes similar to the control as judged by visualization were
compared to the control by PDQuest as described in the “Materials
and methods” section. Only proteins differentially expressed near
or over twofold in at least three of 10 gels and in a statistically
signiﬁcant manner were scored as deregulated proteins. Compar-
ative results indicated that nine deregulated protein spots were
observed in the patients with cancer lesions (Table 2). Five proteins
(spots 1e5) were underexpressed in patients with BTCC whereas
four proteins (spots AeD) were overexpressed (Figure 3 and
Table 2). In addition to nine deregulated proteins, two proteins
(spots 6 and E) were found that were differentially expressed in 2 of
10 gels.3.3. Identiﬁcation of differentially expressed proteins in BTCC urine
specimens
After the urinary proteome comparison, 11 proteins with altered
expression were attempted to be identiﬁed. For this purpose, the
spots were excised, digested with trypsin, and analyzed by MS/MS
as described in the “Materials and methods” section. Mass spec-
trometry identiﬁed six proteins because more than one protein
spot represented the same protein and protein spot 3 could not be
recognized (Table 3). The deregulated proteins were recognized as
human haptoglobin precursor (spots 1 and 2), heparan sulfate
proteoglycan perlecan (spots 4, B, and D), inter-〈-trypsin inhibitor
heavy chain H4 precursor (spot 6), a-1-microglobulin/Bik protein
(AMBP) precursor (spots 5 and E), peroxiredoxin 2 (spot A), and
protease serine 1 fragment (spot C; Table 2). The apparent molec-
ular masses (MW) and isoelectric point (pI)s of most proteins were
not comparable to the theoretical values deduced from protein
database and protein coverage was low.Please cite this article in press as: Su C-C, et al., Searching urinary tu
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Using proteomics techniques, we have proﬁled the protein
expression of urinary specimens collected from healthy volunteers
and the patients with BTCC from the southwestern coast of Taiwan.
Eleven deregulated proteins were found in the comparison of uri-
nary proteomes of patients with BTCC with those of the controls
and six proteins were identiﬁed by MS/MS. Bakun et al7 reported
that the protein proﬁle of 24 proteins of young persons (aged
19e26 years; mean 21 years) is different from those of elderly
persons (aged 72e90 years; mean 79 years). AMBP protein was
discovered by Bakun et al.7 However, the rest of the deregulated
proteins found in this study were not discovered by Bakun et al.7
There is a possibility that deregulated proteins in this study can
be attributed to the age difference.
In this study the theoretical MWs/pIs were not comparable to
those of most identiﬁed proteins. This inconsistency might attri-
bute to the cleavage of intact proteins when they pass through the
urinary system during the process of urine formation or to the
degradation of extracellular matrix due to the outgrowth of the
tumor to the bladder cavity. Consistent with the aforementioned
disparity, the urinary proteomes reported by Orenes-Pi~nero and
colleagues8 showed that the fragments of Ck1, Ck2, Ck10, hapto-
globin protein precursor, and AMBP protein precursor are present
in urine samples of BTCC patients and the MWs/pIs of these protein
fragments are not consistent with the theoretical MW/pI. In addi-
tion, perlecan c-terminal fragments and a-1-microglobulin are
found by Rasmussen et al9 to be present in the urine of patients
with BTCC. However, no deregulated protein found in this study
was correlated with the previous ﬁndings. The difference might be
explained by the analyses of BTCC samples from the different re-
gions of the world. BTCC lesions collected in this study were from
the southwestern coast of Taiwan where blackfoot disease is
endemic and the incidence of BTCC is unusually high. Epidemio-
logical studies indicated that the high incidence of BTCC may be
attributed to the high arsenic content in the drinking water.10 This
is in contrast to the risk factors implicated in BTCC in other coun-
tries, i.e., smoking, chemotherapeutic agents, or industrial dyes.11 In
addition to the different risk factors, the urinary samples have the
intrinsic variations among the different individuals, even among
those having the same genetic background. Therefore, it is possible
to ﬁnd the different deregulated proteins in the urine by analyzing
the cancer lesions derived from the different areas of the world.
Human heparan sulfate proteoglycan perlecan plays multiple
roles as a structural component of basement membranes, and
functional regulator of several growth-factor signaling pathwaysmor-associated proteins for bladder transitional cell carcinoma in
15), http://dx.doi.org/10.1016/j.urols.2015.08.009
Table 3
Summary of the protein identiﬁcation by tandem mass spectrometry.










Downregulation in patients with BTTC
Spot 1 Human haptoglobin
precursor
21.4/6.41 P00738 45.2/6.13 12 LRTEGDGVYTLNNEK (2, 4.29, 0.01, 1); LRTEGDGVYTLNNEKQW
INK (2, 4.22, 0.37,1); LRTEGDGVY
TLNDK (2, 3.85, 0.24, 2); TEGDGV
YTLNDK (2, 3.37, 0.22, 1); LRTEG
DGVYTLNDKK (3, 3.08, 0.22, 2); T
EGDGVYTLNDKK (2, 3.06, 0.09, 2);
TEGDGVYTLNDKKQWINK (3, 2.74, 0.05, 1)
Spot 2 Human haptoglobin
precursor
20.1/6.42 P00738 45.2/6.13 9.9 LRTEGDGVYTLNNEKQWINK (3, 4.12, 0.27, 1); LRTEGDGVYTLND
KK (2, 3.39, 0.01, 2); TEGDGVYTL
NDK (2, 2.77, 0.42, 1); TEGDGVYT
LNDKKQWINK (3, 2.54, 0.17, 1); L
RTEGDGVYTLNDK (2, 2.39, 0.33, 5)
Spot 3 Unknown 19.5/6.42 d d d d
Spot 4 Heparan sulfate
proteoglycan perlecan
21.4/6.26 P98160 468.8/6.06 1.4 SLPEVPETIELEVR (2, 3.02, 0.49,1); RGSIQVDGEELVSGR (2, 3.37, 0.5, 1);
GSVYIGGAPDVATLTGGR (2, 2.72, 0.37, 1)
Spot 5 AMBP protein precursor 32.7/4.77 P02760 38.99/5.95 31 IYGKWYNLAIGSTCPWLK (3, 4.81, 0.32,1);
WYNLAIGSTCPWLK (2, 4.68, 0.45, 1); TVSTLVLGEGATEA
EISMTSTR (2, 2.95, 0.37,1); FIQLW
AFDAVK (2, 3.78, 0.35,1); GVCEET
SGAYEKTDTDGKFLYHK (3, 2.63, 0.06, 2); ETLLQDFR (2, 2.95, 0.13, 2);
APQLRETLLQDFR (2, 2.79, 0.13, 2);




36.4/4.85 Q14624 103.36/6.51 9.2 QGPVNLLSDPEQGVEVTGQYER (2, 4.77, 0.57, 1); EKAGFSWIEVTF
K (2, 3.31, 0.48,1); PLVWVHASPEH
VVVTR(2, 4.69, 0.52, 1); KETLFSV
MPGLK (2, 3.65, 0.41, 1); TGLLLLS
DPDK (2, 2.27, 0.33, 9)
Upregulation in patients with BTCC
Spot A Peroxiredoxin 2 24.3/5.65 P32119 21.9/5.66 29 GLFIIDGKGVLR (2, 2.99, 0.23, 3);
LSEDYGVLKTDEGIAYR (2, 2.74, 0.42, 1);
QITVNDLPVGR (2, 2.00, 0.38, 9);
RLSEDYGVLKTDEGIAYR (3, 1.65, 0.07, 55)
Spot B Heparan sulfate
proteoglycan perlecan
25.1/5.91 P98160 468.8/6.06 4 SLPEVPETIELEVR (2, 3.62, 0.46, 1); TSTASGLLLWQGVEVGEAGQ
GK (2, 5.77, 0.55, 1); DFISLGLQDG
HLVFR (2, 3.32, 0.45, 1); VSEDPIN
DGEWHR (2, 3.58, 0.47, 1); GSIQV
DGEEVSGRSPGPNVAVNAK (3, 5.16, 0.45, 1); GSVYIGGAPDVATL
TGGR (2, 5.24, 0.39, 1); FSSGITGC
VK (2, 2.10, 0.47, 1); NLVLHSARP
GAPPPQPLDLQHR (3, 4.34, 0.45, 1)
Spot C Protease serine
1 fragment
20.4/4.82 Q86W20 9.1/10.28 35.7 LGEHNIKVLEGNEQFINAAK (3, 3.5, 0.12, 1);
VLEGNEQFINAAK (2, 3.07, 0.42, 1); TLNNDIMLIK (2, 1.85, 0.01, 6)
Spot D Heparan sulfate
proteoglycan perlecan
25.2/6.46 P98160 468.8/6.06 4.4 SLPEVPETIELEVR (2, 3.98, 0.55, 1); TSTASGLLLWQGVEVGEAGQ
GK (2, 6.19, 0.56, 1); DFISLGLQDG
HLVFR (2, 5.26, 0.54,1); YQLGSGE
AR (2, 2.16, 0.24,1); LVSEDPINDGE
WHR (2, 4.39, 0.56, 1); RGSIQVDG EELVSGR (2, 5.86, 0.58, 1); SPGPN
VAVNAKGSVYIGGAPDVATLTGGR (3, 4.58, 0.41, 1);
FSSGITGCVK (2, 0.39, 0.41,1); NLVLHSARPGAPP
PQPLDLQHR (3, 6.29, 0.56, 1)
Spot E AMBP protein precursor 19.4/4.8 P02760 38.99/5.95 25 AFIQLWAFDAVK (2, 3.39, 0.44, 1); YNLAIGSTCPWLK (2, 2.69, 0.4, 1);
VVAQGVGIPEDSIFTMADR (2, 2.37, 0.21, 1);
ETLLQDFR (2, 2.04, 0.16,2); TVAACNLPIVR (2, 1.64, 0.03, 6)
AMBP ¼ a-1-microglobulin/Bik protein; BTCC ¼ bladder transitional cell carcinoma; MW ¼ molecular weight; pI ¼ isoelectric point.
a The numbers in the parenthesis following the peptide sequence denote the charge, Xcorr, dCn, and Rsp, respectively.
C.-C. Su et al. / Urological Science xxx (2015) 1e8 7and angiogenesis.12 Overexpressed perlecan appears to be related
to the invasiveness of the melanoma cells.13 Perlecan is also upre-
gulated in the secretome of pancreatic cancer.14 Our data suggested
that overexpression of perlecan might facilitate the development of
bladder cancer.
AMBP can be cleaved to form bikunin (Bik) and a-1-
microglobulin. In our study, two differentially expressed protein
spots (spots 5 and E) were identiﬁed as AMBP. Based on the pep-
tides identiﬁed by MS/MS and the results by Blastp search, spots 5
and E might represent a-1-microglobulin and Bik, respectively. Bik,
also called urinary trypsin inhibitor, is the light chain of inter-Please cite this article in press as: Su C-C, et al., Searching urinary tu
southwestern Taiwan using gel-based proteomics, Urological Science (20alpha-trypsin inhibitor (IaI) which is composed of two heavy and
one light chains.15 Inhibition of immune cell's serine proteases by
Bik augments cell proliferation/stability and protects the extracel-
lular matrix in arterial walls and connective tissue.15 Bik is found to
be overexpressed in several tumors, e.g., colon, pancreas, ovarian
cancer, and stomach.15,16 In addition to the light chain with diag-
nostic value, the fragments of IaI heavy chain H4 (ITIH4) of IaI have
been shown to be a deregulated serum protein of ovarian17 and
lung tumors18 and the ITIH4 fragmentation patterns within the
proline-rich region (PRR) are highly associated ovarian, breast, co-
lon, prostate, and pancreatic cancers.19 a-1-microglobulin is widelymor-associated proteins for bladder transitional cell carcinoma in
15), http://dx.doi.org/10.1016/j.urols.2015.08.009
C.-C. Su et al. / Urological Science xxx (2015) 1e88distributed in extravascular compartment of all tissues. Many
studies suggested that a-1-microglobulin may be a biomarker for
the tubular or renal diseases.20 Based on the previously docu-
mented ﬁndings, a-1-microglobulin and ITIH4 might be the po-
tential biomarkers for the diagnosis of BTCC, although larger
amounts of specimens are required for the further investigation.
Haptoglobin (Hp) is a hemoglobin-binding protein that can
scavenge the oxidative stress and cellular toxicity caused by the
heme iron in free hemoglobin (Hb) to avoid the blood vessel and
renal damage.21 Many studies indicated that Hp might be a po-
tential serum biomarker22 in lung cancer and the glycosylation
status of haptoglobin might be utilized as a promising diagnostic
biomarker for prostate,23 pancreatic,24 and hepatic cancers.25 In
this study, two haptoglobin fragments were found to be deregu-
lated in ﬁve and six of 10 patients with BTCC, respectively. Hpmight
be a potential diagnostic urinary biomarker for BTCC.
Peroxiredoxins (Prxs) are a family of multifunctional antioxidant
peroxidases. Prxs can protect cells from oxidative stress and
modulate the signal transduction pathways that utilize c-Abl, cas-
pases, nuclear factor-kB, and activator protein-1 and exploit
hydrogen peroxide as a second messenger molecule to inﬂuence
cell proliferation and apoptosis.26
In this study, 11 deregulated proteins were observed in the
urinary specimens of patients with BTCC from the southwestern
coast of Taiwan where blackfoot disease is endemic and the un-
usually high incidence of BTCC in this area might attribute to high
arsenic content in the drinking water. These deregulated proteins
might be altered by arsenic in the local environment. It is possible
that long-term arsenic-induced alteration of these deregulated
proteins, most of which were extracellular matrix-related proteins
and may play roles in regulating the immune response, signal
transduction, and tumor invasions, might be involved in BTCC
development in southwestern Taiwan. In addition, based on the
identiﬁed proteins it was proposed that outgrowth of bladder tu-
mor may change the arrangement of extracellular matrix, cell
signaling, and immune response. Therefore, the fragments of most
of these proteins were shed into the urine of patients with BTCC.
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